Sat.Nov 06, 2021

article thumbnail

Abbott launches new initiative to drive diversity in medical research and improve care among under-represented populations

The Pharma Data

Abbott (NYSE ABT) moment blazoned the launch of a new action designed to help produce a further inclusive clinical trial ecosystem through new approaches to training, education, and perfecting the clinical exploration structure within theU.S. This trouble builds on Abbott’s commitment of engaging populations who have historically been under- represented in medical exploration and will ameliorate health by adding access to innovative treatment options available within the trials process and

article thumbnail

New tentative approval for Radius Health drug abaloparatide

Drug Patent Watch

Abaloparatide is the generic ingredient in one branded drug marketed by Radius Health Inc and is included in one NDA. There are four patents protecting this compound. This ingredient has…. The post New tentative approval for Radius Health drug abaloparatide appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Microdose Psychedelic Insights Provides an Update on the Upcoming Wonderland: Miami Conference, Shares Details on Newly Confirmed Participants and Unmissable Fireside Chats

BioTech 365

Microdose Psychedelic Insights Provides an Update on the Upcoming Wonderland: Miami Conference, Shares Details on Newly Confirmed Participants and Unmissable Fireside Chats Microdose Psychedelic Insights Provides an Update on the Upcoming Wonderland: Miami Conference, Shares Details on Newly Confirmed Participants … Continue reading →

40
article thumbnail

Cream dosed drug patent expirations by year

Drug Patent Watch

This chart shows the patent expirations for cream dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Cream dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting

BioTech 365

Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting … Continue reading →

40
article thumbnail

GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease

The Pharma Data

Late-breaking data from the daprodustat ASCEND-ND and ASCEND-D trials at the American Society of Nephrology’s Kidney Week 2021 confirms the potential for a new oral treatment for patients with anaemia due to chronic kidney disease in both non-dialysis and dialysis settings Data from five Phase III studies demonstrated that daprodustat improved or maintained haemoglobin within target levels, without increased cardiovascular risk when compared to standard of care Pivotal trials in non-dialysis and

Trials 52

More Trending

article thumbnail

Democrats Choosing Less Risky Path on Drug Prices

NY Times

Experts say recent compromises could create less harm in balancing innovation with profits.

Drugs 93
article thumbnail

Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

BioTech 365

Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over … Continue reading →

52